Takeda Pharmaceutical has been granted a patent for a method to treat small cell lung cancer. The method involves administering a specific Aurora kinase inhibitor in combination with a platin, such as cisplatin or carboplatin, detailing specific dosages for each component. GlobalData’s report on Takeda Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Takeda Pharmaceutical, Cancer treatment biomarkers was a key innovation area identified from patents. Takeda Pharmaceutical's grant share as of June 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.
Cancer treatment using aurora kinase inhibitor and platin
A recently granted patent (US12042499B2) outlines a novel method for treating small cell lung cancer through a specific combination of pharmaceutical agents. The primary active ingredient is 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid, or its pharmaceutically acceptable salts, administered at a dosage of approximately 48.6 mg twice daily. This compound is combined with a platinum-based drug, either cisplatin or carboplatin, with cisplatin dosed at about 12 mg/m² per day or carboplatin administered at an area under the curve (AUC) of about 4.6 mg/mL/min. Notably, the claims specify that these two agents are the only active ingredients utilized in the treatment regimen.
The patent further details the administration schedule for both agents. The pyrimido compound is to be given twice daily on specific days within a 28-day cycle, while the platinum agent can be administered on day 1, or on days 1, 8, and 15 of the same cycle. The method allows for both sequential and simultaneous administration of the two drugs, with the pyrimido compound being administered orally and the platinum agent intravenously. This comprehensive approach aims to enhance the efficacy of treatment for patients suffering from small cell lung cancer, providing a structured regimen that could potentially improve patient outcomes.
To know more about GlobalData’s detailed insights on Takeda Pharmaceutical, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
